Bridges Beyond Borders

Bridges Beyond Borders

BEIJING, June 25, 2025 /PRNewswire/ -- A report from China Report ASEAN: On April 12, a 200-kilogram shipment of fresh coconuts departed from Jakarta, Indonesia, bound for Changle Airport in Fuzhou, southeast China's Fujian Province. After customs...

MedHub-AI Receives PMDA Approval in Japan for AutocathFFR®

MedHub-AI Receives PMDA Approval in Japan for AutocathFFR®

TEL AVIV, Israel, June 18, 2025 /PRNewswire/ -- MedHub-AI, a global leader in AI-powered cardiovascular diagnostics, announced today that the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has approved AutocathFFR®, the company's...

PharmaResearch Spin-Off into Holding and Aesthetics Companies Approved by Board of Directors

PharmaResearch Spin-Off into Holding and Aesthetics Companies Approved by Board of Directors

SEONGNAM, South Korea, June 13, 2025 /PRNewswire/ -- PharmaResearch announced on June 13 that its board of directors has approved a corporate spin-off, resulting in the formation of two distinct entities: PharmaResearch Holdings, which will remain...

Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab

Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab

HONG KONG, June 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has approved the company's first- in-class PD-1/CTLA-4 bispecific antibody,...

JW Therapeutics Announces Approval of Relmacabtagene Autoleucel Injection (Carteyva®) for Marketing in Macao

JW Therapeutics Announces Approval of Relmacabtagene Autoleucel Injection (Carteyva®) for Marketing in Macao

SHANGHAI, June 4, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that its new drugapplication...

Autoliv Capital Markets Day - sustainable increase in shareholder returns with increased dividend and new stock repurchase program

Autoliv Capital Markets Day - sustainable increase in shareholder returns with increased dividend and new stock repurchase program

STOCKHOLM, June 4, 2025 /PRNewswire/ -- Autoliv, Inc. (NYSE: ALV) (SSE: ALIVsdb), the worldwide leader in automotive safety systems, hosts a Capital Markets Day (CMD) today. Members of Autoliv management will outline the Company's strategy, growth...

XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS

XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS

SUZHOU, China, June 3, 2025 /PRNewswire/ -- XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received seven...

NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA

NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA

SKYTROFA® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency.[ 1] SINGAPORE, May 30, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised...

Kexing Biopharm's GB18 project received clearance of IND application from NMPA and FDA

Kexing Biopharm's GB18 project received clearance of IND application from NMPA and FDA

SHENZHEN, China, May 29, 2025 /PRNewswire/ -- On May 26th, Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its independently developed...

SHEIN's Science-Based Net-Zero Target is Approved by SBTi

SHEIN's Science-Based Net-Zero Target is Approved by SBTi

SINGAPORE, May 27, 2025 /PRNewswire/ -- As a global online fashion and lifestyle retailer, we have reached a milestone in our climate journey with the Science Based Targets initiative (SBTi) validating our net-zero science-based target by 2050 and...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • menu
    menu